Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Price Requirement
Trinity Biotech plc (Nasdaq: TRIB) announced on April 19, 2023, that it has received a notice from Nasdaq regarding non-compliance with Listing Rule 555(a)(2), due to the bid price of its American depositary shares falling below $1.00 for 30 consecutive business days.
The company has until October 16, 2023, to regain compliance by achieving a closing bid price of $1.00 for at least ten consecutive business days. If not compliant, Trinity may qualify for an additional 180-day grace period if it meets other listing requirements. Management will actively monitor the bid price and explore options to regain compliance.
- Management intends to actively monitor bid prices and explore options to regain compliance.
- The company's ADS bid price has fallen below $1.00 for 30 consecutive business days.
- Failure to regain compliance by October 16, 2023, may lead to delisting.
DUBLIN, Ireland, April 24, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, today announced that on April 19, 2023 the Company received notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with Nasdaq Listing Rule 555(a)(2), as the minimum bid price of the Company’s American depositary shares (“ADSs”) has been below US
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), Trinity has a period of 180 calendar days, or until October 16, 2023 to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s ADSs must meet or exceed US
Trinity’s management intends to actively monitor the bid price for its ADSs and will consider all available options to regain compliance with the Nasdaq minimum bid price requirement.
About Trinity Biotech
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com
Forward-Looking Statements
Certain statements made in this release that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “estimate”, “project”, “intend”, “expect”, “believe” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of Trinity Biotech to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, but not limited to, the results of research and development efforts, risks associated with the outbreak and global spread of the coronavirus (COVID-19), the effect of regulation by the U.S. Food and Drug Administration and other agencies, the impact of competitive products, product development commercialization and technological difficulties. For additional information regarding these and other risks and uncertainties associated with Trinity Biotech’s business, reference is made to our reports filed from time to time with the U.S. Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements for any reason.
Contact: | Trinity Biotech plc | Lytham Partners, LLC |
John Gillard | Joe Diaz | |
(353)-1-2769800 | (1)-602-889-9700 | |
E-mail investorrelations@trinitybiotech.com |
FAQ
What does the Nasdaq notice mean for Trinity Biotech (TRIB)?
What steps can Trinity Biotech take to regain compliance by October 16, 2023?
What happens if Trinity Biotech (TRIB) fails to regain compliance with Nasdaq's rules?
How long does Trinity Biotech have to comply with Nasdaq's listing requirements?